Accolade (ACCD) Stock Forecast, Price Target & Predictions
ACCD Stock Forecast
Accolade stock forecast is as follows: an average price target of $14.81 (represents a 254.31% upside from ACCD’s last price of $4.18) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
ACCD Price Target
The average price target for Accolade (ACCD) is $14.81 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $52.00 to $5.00. This represents a potential 254.31% upside from ACCD's last price of $4.18.
ACCD Analyst Ratings
According to 14 Wall Street analysts, Accolade's rating consensus is 'Buy'. The analyst rating breakdown for ACCD stock is 0 'Strong Buy' (0.00%), 8 'Buy' (57.14%), 6 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Accolade Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | David Grossman | Stifel Nicolaus | $8.00 | $3.58 | 123.46% | 91.39% |
| Jun 28, 2024 | Richard Close | Canaccord Genuity | $13.00 | $6.39 | 103.44% | 211.00% |
| Jun 28, 2024 | Ryan MacDonald | Needham | $8.00 | $6.39 | 25.20% | 91.39% |
| Jun 28, 2024 | Jailendra Singh | Truist Financial | $9.00 | $6.39 | 40.85% | 115.31% |
| Jun 28, 2024 | Stephanie Davis | Barclays | $5.50 | $6.39 | -13.93% | 31.58% |
| Jun 28, 2024 | Gil Luria | D.A. Davidson | $5.00 | $6.39 | -21.75% | 19.62% |
| Apr 30, 2024 | Stan Berenshteyn | Wells Fargo | $10.00 | $8.19 | 22.10% | 139.23% |
| Oct 04, 2023 | Ricky Goldwasser | Morgan Stanley | $14.00 | $10.03 | 39.58% | 234.93% |
| Jun 30, 2023 | Ryan MacDonald | Needham | $17.00 | $13.61 | 24.91% | 306.70% |
| Jun 30, 2023 | Ryan MacDonald | Needham | $14.27 | $12.64 | 12.90% | 241.39% |
The latest Accolade stock forecast, released on Jun 28, 2024 by David Grossman from Stifel Nicolaus, set a price target of $8.00, which represents a 123.46% increase from the stock price at the time of the forecast ($3.58), and a 91.39% increase from ACCD last price ($4.18).
Accolade Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 6 | 8 |
| Avg Price Target | - | $8.08 | $9.06 |
| Last Closing Price | $4.18 | $4.18 | $4.18 |
| Upside/Downside | -100.00% | 93.30% | 116.75% |
In the current month, the average price target of Accolade stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Accolade's last price of $4.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 28, 2024 | Needham | Buy | Buy | Hold |
| Jun 28, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Apr 30, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Feb 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Feb 26, 2024 | Raymond James | Underperform | Underperform | Hold |
| Jan 19, 2024 | Wells Fargo | Buy | Buy | Hold |
| Jan 09, 2024 | Wedbush | Outperform | Outperform | Hold |
| Oct 05, 2023 | Raymond James | Outperform | Outperform | Hold |
| Oct 04, 2023 | Needham | Buy | Buy | Hold |
Accolade's last stock rating was published by Canaccord Genuity on Jun 28, 2024. The company gave ACCD a "Buy" rating, the same as its previous rate.
Accolade Financial Forecast
Accolade Revenue Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $96.86M | $93.23M | - | - | $87.64M | $85.53M | - | $83.45M | $73.29M | $59.53M | - | $38.44M | $36.79M | $35.89M |
| Avg Forecast | $178.20M | $143.38M | $137.52M | $137.11M | $160.72M | $125.54M | $120.89M | $122.73M | $141.60M | $109.95M | $105.00M | $105.95M | $123.91M | $96.16M | $94.09M | $90.82M | $99.44M | $87.53M | $80.17M | $81.97M | $91.58M | $75.89M | $70.37M | $55.67M | $56.64M | $36.25M | $34.62M | $34.14M |
| High Forecast | $178.20M | $143.38M | $137.52M | $137.11M | $160.72M | $125.54M | $120.89M | $122.73M | $141.60M | $109.95M | $105.22M | $105.95M | $123.91M | $96.64M | $94.09M | $90.82M | $99.44M | $87.53M | $96.20M | $98.36M | $93.55M | $77.53M | $71.89M | $56.87M | $57.86M | $37.03M | $35.37M | $34.87M |
| Low Forecast | $178.20M | $143.38M | $137.52M | $137.11M | $160.72M | $125.54M | $120.89M | $122.73M | $141.60M | $109.95M | $104.71M | $105.95M | $123.91M | $95.39M | $94.09M | $90.82M | $99.44M | $87.53M | $64.13M | $65.58M | $88.98M | $73.74M | $68.38M | $54.09M | $55.03M | $35.22M | $33.64M | $33.17M |
| # Analysts | 8 | 5 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 10 | 5 | 9 | 10 | 5 | 5 | 8 | 9 | 16 | 16 | 7 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.03% | - | - | 1.09% | 1.04% | - | 1.10% | 1.04% | 1.07% | - | 1.06% | 1.06% | 1.05% |
Accolade's average Quarter revenue forecast for Dec 23 based on 10 analysts is $96.16M, with a low forecast of $95.39M, and a high forecast of $96.64M. ACCD's average Quarter revenue forecast represents a -0.72% decrease compared to the company's last Quarter revenue of $96.86M (Aug 23).
Accolade EBITDA Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 10 | 5 | 9 | 10 | 5 | 5 | 8 | 9 | 16 | 16 | 7 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-20.38M | $-25.94M | - | - | $-34.47M | $-34.81M | - | $37.82M | $-63.41M | $-39.37M | - | $-14.42M | $-10.96M | $-10.71M |
| Avg Forecast | $-21.12M | $-17.00M | $-16.30M | $-16.25M | $-19.05M | $-14.88M | $-14.33M | $-14.55M | $-16.78M | $-13.03M | $-12.45M | $-12.56M | $-14.20M | $-11.40M | $-11.15M | $-10.77M | $-12.91M | $-10.38M | $-69.36M | $-450.71M | $-11.73M | $-13.84M | $-63.06M | $-25.75M | $-10.33M | $-15.65M | $-9.04M | $-6.23M |
| High Forecast | $-21.12M | $-17.00M | $-16.30M | $-16.25M | $-19.05M | $-14.88M | $-14.33M | $-14.55M | $-16.78M | $-13.03M | $-12.41M | $-12.56M | $-11.36M | $-11.31M | $-11.15M | $-10.77M | $-10.32M | $-10.38M | $-55.49M | $-360.57M | $-9.39M | $-13.45M | $-50.44M | $-20.60M | $-10.04M | $-12.52M | $-7.23M | $-6.05M |
| Low Forecast | $-21.12M | $-17.00M | $-16.30M | $-16.25M | $-19.05M | $-14.88M | $-14.33M | $-14.55M | $-16.78M | $-13.03M | $-12.47M | $-12.56M | $-17.04M | $-11.46M | $-11.15M | $-10.77M | $-15.49M | $-10.38M | $-83.23M | $-540.85M | $-14.08M | $-14.14M | $-75.67M | $-30.90M | $-10.55M | $-18.78M | $-10.85M | $-6.36M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.83% | 2.41% | - | - | 0.50% | 0.08% | - | -2.73% | 1.01% | 1.53% | - | 0.92% | 1.21% | 1.72% |
7 analysts predict ACCD's average Quarter EBITDA for Mar 22 to be $-11.73M, with a high of $-9.39M and a low of $-14.08M. This is -131.02% lower than Accolade's previous annual EBITDA (Nov 21) of $37.82M.
Accolade Net Income Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 10 | 5 | 9 | 10 | 5 | 5 | 8 | 9 | 16 | 16 | 7 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-32.83M | $-38.23M | - | - | $-46.52M | $-342.82M | - | $22.50M | $-62.36M | $-48.71M | - | $-16.59M | $-15.37M | $-13.96M |
| Avg Forecast | $781.19K | $-19.92M | $-25.39M | $-32.03M | $5.66M | $-22.38M | $-28.29M | $-29.07M | $732.06K | $-25.82M | $-34.70M | $-37.50M | $-26.83M | $-34.93M | $-42.13M | $-48.24M | $-24.39M | $-48.30M | $-68.22M | $-461.91M | $-22.17M | $48.99M | $-62.01M | $-31.86M | $-6.98M | $-18.02M | $-12.68M | $-27.98M |
| High Forecast | $781.19K | $-19.92M | $-25.39M | $-32.03M | $5.66M | $-22.38M | $-28.29M | $-29.07M | $732.06K | $-25.82M | $-32.39M | $-37.50M | $-21.46M | $-28.10M | $-42.13M | $-48.24M | $-19.51M | $-48.30M | $-54.57M | $-369.53M | $-17.74M | $58.79M | $-49.61M | $-25.49M | $-6.72M | $-14.41M | $-10.14M | $-26.95M |
| Low Forecast | $781.19K | $-19.92M | $-25.39M | $-32.03M | $5.66M | $-22.38M | $-28.29M | $-29.07M | $732.06K | $-25.82M | $-39.33M | $-37.50M | $-32.20M | $-39.49M | $-42.13M | $-48.24M | $-29.27M | $-48.30M | $-81.86M | $-554.29M | $-26.61M | $39.19M | $-74.42M | $-38.23M | $-7.18M | $-21.62M | $-15.22M | $-28.77M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.78% | 0.79% | - | - | 0.68% | 0.74% | - | 0.46% | 1.01% | 1.53% | - | 0.92% | 1.21% | 0.50% |
Accolade's average Quarter net income forecast for Mar 22 is $-22.17M, with a range of $-26.61M to $-17.74M. ACCD's average Quarter net income forecast represents a -198.54% decrease compared to the company's last Quarter net income of $22.50M (Nov 21).
Accolade SG&A Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 10 | 5 | 9 | 10 | 5 | 5 | 8 | 9 | 16 | 16 | 7 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $40.34M | $41.11M | - | - | $45.96M | $45.85M | - | $46.08M | $50.18M | $46.97M | - | $17.06M | $14.33M | $12.98M |
| Avg Forecast | $81.45M | $65.53M | $62.86M | $62.67M | $73.46M | $57.38M | $55.25M | $56.10M | $64.72M | $50.25M | $47.99M | $48.43M | $41.23M | $43.95M | $43.00M | $41.51M | $37.48M | $40.01M | $54.89M | $61.78M | $34.07M | $35.80M | $49.90M | $30.72M | $26.71M | $18.52M | $11.83M | $16.10M |
| High Forecast | $81.45M | $65.53M | $62.86M | $62.67M | $73.46M | $57.38M | $55.25M | $56.10M | $64.72M | $50.25M | $48.09M | $48.43M | $49.47M | $44.17M | $43.00M | $41.51M | $44.98M | $40.01M | $65.86M | $74.14M | $40.89M | $36.57M | $59.88M | $36.87M | $27.29M | $22.22M | $14.19M | $16.45M |
| Low Forecast | $81.45M | $65.53M | $62.86M | $62.67M | $73.46M | $57.38M | $55.25M | $56.10M | $64.72M | $50.25M | $47.86M | $48.43M | $32.98M | $43.60M | $43.00M | $41.51M | $29.98M | $40.01M | $43.91M | $49.42M | $27.26M | $34.78M | $39.92M | $24.58M | $25.96M | $14.82M | $9.46M | $15.65M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.94% | 0.99% | - | - | 0.84% | 0.74% | - | 1.29% | 1.01% | 1.53% | - | 0.92% | 1.21% | 0.81% |
Accolade's average Quarter SG&A projection for Dec 23 is $43.95M, based on 10 Wall Street analysts, with a range of $43.60M to $44.17M. The forecast indicates a 8.97% rise compared to ACCD last annual SG&A of $40.34M (Aug 23).
Accolade EPS Forecast
| Mar 27 | Dec 26 | Aug 26 | May 26 | Mar 26 | Dec 25 | Aug 25 | May 25 | Mar 25 | Dec 24 | Aug 24 | May 24 | Mar 24 | Dec 23 | Aug 23 | May 23 | Mar 23 | Dec 22 | Aug 22 | May 22 | Mar 22 | Nov 21 | Aug 21 | May 21 | Mar 21 | Nov 20 | Aug 20 | May 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 8 | 5 | 5 | 5 | 8 | 4 | 4 | 4 | 7 | 5 | 10 | 5 | 9 | 10 | 5 | 5 | 8 | 9 | 16 | 16 | 7 | 9 | 9 | 9 | 8 | 9 | 9 | 9 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.43 | $-0.52 | - | - | $-0.66 | $-4.92 | - | $0.34 | $-0.97 | $-0.84 | - | $-0.32 | $-0.47 | $-0.30 |
| Avg Forecast | $0.01 | $-0.26 | $-0.33 | $-0.41 | $0.07 | $-0.29 | $-0.36 | $-0.37 | $0.01 | $-0.33 | $-0.44 | $-0.48 | $-0.11 | $-0.45 | $-0.54 | $-0.62 | $-0.41 | $-0.62 | $1.27 | $1.15 | $-0.42 | $-0.78 | $-0.59 | $-0.35 | $-0.09 | $-0.33 | $-0.40 | $-0.37 |
| High Forecast | $0.01 | $-0.26 | $-0.33 | $-0.41 | $0.07 | $-0.29 | $-0.36 | $-0.37 | $0.01 | $-0.33 | $-0.41 | $-0.48 | $-0.11 | $-0.36 | $-0.54 | $-0.62 | $-0.41 | $-0.62 | $1.27 | $1.18 | $-0.41 | $-0.75 | $-0.57 | $-0.34 | $-0.09 | $-0.32 | $-0.39 | $-0.35 |
| Low Forecast | $0.01 | $-0.26 | $-0.33 | $-0.41 | $0.07 | $-0.29 | $-0.36 | $-0.37 | $0.01 | $-0.33 | $-0.50 | $-0.48 | $-0.11 | $-0.51 | $-0.54 | $-0.62 | $-0.41 | $-0.62 | $1.27 | $1.09 | $-0.43 | $-0.80 | $-0.61 | $-0.36 | $-0.09 | $-0.34 | $-0.41 | $-0.38 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.80% | 0.84% | - | - | -0.52% | -4.26% | - | -0.44% | 1.65% | 2.39% | - | 0.96% | 1.17% | 0.81% |
According to 7 Wall Street analysts, Accolade's projected average Quarter EPS for Mar 22 is $-0.42, with a low estimate of $-0.43 and a high estimate of $-0.41. This represents a -224.26% decrease compared to ACCD previous annual EPS of $0.34 (Nov 21).
Accolade Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACCD | Accolade | $4.18 | $14.81 | 254.31% | Buy |
| HCAT | Health Catalyst | $8.74 | $29.25 | 234.67% | Buy |
| DH | Definitive Healthcare | $4.56 | $9.50 | 108.33% | Hold |
| CERT | Certara | $10.93 | $21.75 | 98.99% | Hold |
| PRVA | Privia Health Group | $19.07 | $33.82 | 77.35% | Buy |
| PINC | Premier | $20.48 | $33.25 | 62.35% | Hold |
| PHR | Phreesia | $24.05 | $36.31 | 50.98% | Buy |
| EVH | Evolent Health | $30.84 | $44.00 | 42.67% | Buy |
| CMAX | CareMax | $2.18 | $2.60 | 19.27% | Hold |
ACCD Forecast FAQ
Is Accolade a good buy?
Yes, according to 14 Wall Street analysts, Accolade (ACCD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 57.14% of ACCD's total ratings.
What is ACCD's price target?
Accolade (ACCD) average price target is $14.81 with a range of $5 to $52, implying a 254.31% from its last price of $4.18. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Accolade stock go up soon?
According to Wall Street analysts' prediction for ACCD stock, the company can go up by 254.31% (from the last price of $4.18 to the average price target of $14.81), up by 1144.02% based on the highest stock price target, and up by 19.62% based on the lowest stock price target.
Can Accolade stock reach $6?
ACCD's average twelve months analyst stock price target of $14.81 supports the claim that Accolade can reach $6 in the near future.
Did the ACCD's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Aug 2023), Accolade's revenue was $96.86M, beating the average analysts' forecast of $94.09M by 2.95%. The company's EBITDA was $-20.377M, beating the average prediction of $-11.153M by 82.71%. Accolade's net income was $-32.825M, missing the average estimation of $-42.129M by -22.08%. The company's SG&A was $40.34M, missing the average forecast of $43M by -6.20%. Lastly, the company's EPS was $-0.43, missing the average prediction of $-0.539 by -20.27%